Analysts Set Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Target Price at $71.40

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has received an average recommendation of “Buy” from the eight analysts that are presently covering the firm, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $71.40.

A number of research firms have recently issued reports on ARCT. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcturus Therapeutics in a research report on Monday, September 9th. Leerink Partners initiated coverage on Arcturus Therapeutics in a report on Monday, August 12th. They issued an “outperform” rating and a $70.00 price target for the company. HC Wainwright restated a “buy” rating and set a $63.00 price objective on shares of Arcturus Therapeutics in a report on Friday, November 8th. Finally, Leerink Partnrs raised Arcturus Therapeutics to a “strong-buy” rating in a research note on Monday, August 12th.

Arcturus Therapeutics Stock Up 1.6 %

Shares of NASDAQ ARCT opened at $18.64 on Friday. The stock has a market cap of $504.96 million, a PE ratio of -8.40 and a beta of 2.64. The business has a 50-day moving average price of $19.86 and a 200 day moving average price of $23.11. Arcturus Therapeutics has a 52-week low of $14.93 and a 52-week high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT) last released its earnings results on Thursday, November 7th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.44. The business had revenue of $41.67 million for the quarter, compared to analyst estimates of $49.16 million. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. During the same quarter in the previous year, the company posted ($0.61) earnings per share. Sell-side analysts anticipate that Arcturus Therapeutics will post -2.31 earnings per share for the current year.

Insider Activity at Arcturus Therapeutics

In other Arcturus Therapeutics news, COO Pad Chivukula sold 12,000 shares of the stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $20.76, for a total transaction of $249,120.00. Following the transaction, the chief operating officer now directly owns 435,334 shares in the company, valued at $9,037,533.84. This represents a 2.68 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 15.30% of the company’s stock.

Institutional Trading of Arcturus Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Russell Investments Group Ltd. bought a new position in shares of Arcturus Therapeutics during the first quarter valued at approximately $40,000. nVerses Capital LLC acquired a new stake in Arcturus Therapeutics in the third quarter worth approximately $42,000. Quest Partners LLC boosted its stake in Arcturus Therapeutics by 3,283.5% during the second quarter. Quest Partners LLC now owns 3,688 shares of the biotechnology company’s stock valued at $90,000 after buying an additional 3,579 shares in the last quarter. CANADA LIFE ASSURANCE Co boosted its position in shares of Arcturus Therapeutics by 10.5% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,492 shares of the biotechnology company’s stock valued at $152,000 after purchasing an additional 428 shares in the last quarter. Finally, Public Employees Retirement System of Ohio boosted its holdings in Arcturus Therapeutics by 63.8% during the first quarter. Public Employees Retirement System of Ohio now owns 4,620 shares of the biotechnology company’s stock worth $156,000 after buying an additional 1,800 shares in the last quarter. 94.54% of the stock is owned by institutional investors.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.